991. Clinical Yield of Routine Use of Molecular Testing for Adult Outpatients with Diarrhea
Session: Oral Abstract Session: Diagnostics and Why They Matter
Friday, October 6, 2017: 11:00 AM
Room: 05AB
Background: Molecular diagnostics for enteropathogens increase yield while reducing turnaround time. However, many pathogens do not require specific therapy, and the cost is substantial.

Methods: We reviewed use of the FilmArray GI Panel (BioFire Diagnostics, Salt Lake City, Utah) in adult outpatients at the University of Virginia and identified clinical features that could limit testing without reducing yield. We defined yield as a) detection of a pathogen, b) detection of a pathogen for which antimicrobial therapy is indicated or c) detection of a pathogen that can change management, which additionally included viral pathogens in immunocompromised patients.

Results: Between March 23, 2015 and February 25, 2016, we reviewed 452 tests from adult outpatients with diarrhea. A pathogen was detected in 88/452 (19.5%). The most common pathogens were: enteropathogenic E. coli (36; 8.0%), norovirus (17; 3.8%), Campylobacter (7, 1.5%), enteroaggregative E. coli (6, 1.3%), Giardia(6; 1.3%) and sapovirus (5; 1.1%). Based on clinical guidelines, antimicrobial treatment was clearly indicated for 19/452 subjects (4.2%). Limiting testing to patients with an additional enteric symptom (abdominal pain, nausea, vomiting, fecal urgency, tenesmus, or flatulence), a travel history, or an immunocompromising condition would reduce testing by 25.9%, with a treatable pathogen identified in 18/331 (5.4%)(sensitivity 94.7%, specificity 27.7%). Further modifying testing criteria to exclude subjects with vomiting, 18/288 (6.3%) had a treatable pathogen (sensitivity 94.7%, specificity 37.3%), and a pathogen which could change management was detected in 28/288 (9.7%)(sensitivity 96.6%, specificity 38.5%). Excluding immunocompromised subjects or those with a travel history, American College of Gastroenterology guidelines for testing were met by 293/348 (84.2%) with a documented duration of diarrhea, and a treatable pathogen was detected in 8/293 (2.7%) vs. 3/55 (5.5%) who did not meet testing guidelines.

Conclusion: Testing could be reduced by 36.3% without decreasing clinical yield by limiting testing to patients with diarrhea with an additional enteric symptom and no history of vomiting, a travel history, or an immunocompromising condition. ACG guidelines did not improve testing efficiency.

Stephen Clark, MD1, Michael Sidlak, MS2, Amy Mathers, MD3, Melinda Poulter, PhD2 and James Platts-Mills, MD4, (1)Department of Medicine, University of Virginia, Charlottesville, VA, (2)Clinical Microbiology, University of Virginia, Charlottesville, VA, (3)University of Virginia Health System, Charlottesville, VA, (4)Division of Infectious Disease and International Health, University of Virginia, Charlottesville, VA

Disclosures:

S. Clark, None

M. Sidlak, None

A. Mathers, None

M. Poulter, None

J. Platts-Mills, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.